Aldeyra Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Aldeyra Therapeutics wird ein jährliches Gewinn- und Umsatzwachstum von 60% bzw. 47.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 59.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -42.9% betragen.

Wichtige Informationen

60.0%

Wachstumsrate der Gewinne

59.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.5%
Wachstumsrate der Einnahmen	47.2%
Zukünftige Eigenkapitalrendite	-42.9%
Analystenabdeckung	Good
Zuletzt aktualisiert	16 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment

Sep 14

Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization

Aug 04

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?

Aug 03

Aldeyra says trial for dry eye disease candidate reached key goals

Jul 12

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

Apr 19

Aldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming Catalysts

Feb 17

Aldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In Reproxalap

Dec 23

Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet?

Dec 22

Revisiting Aldeyra Therapeutics

Sep 29

Aldeyra Therapeutics: A New Approach To Ocular Inflammatory Diseases With Impressive Clinical Data

Jun 01

Aldeyra Therapeutics EPS beats by $0.01

May 06

Aldeyra's conjunctivitis treatment meets late-stage study main goals

Apr 27

How Many Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Shares Did Insiders Buy, In The Last Year?

Feb 23

Aldeyra announces reproxalap's late-stage dry eye disease trial design

Feb 04

Aldeyra initiates stock offering

Jan 13

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:ALDX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	75	12	-40	N/A	5
12/31/2025	33	-30	-59	N/A	7
12/31/2024	25	-11	-40	N/A	8
3/31/2024	N/A	-30	-31	-31	N/A
12/31/2023	N/A	-38	-30	-30	N/A
9/30/2023	N/A	-46	-42	-42	N/A
6/30/2023	N/A	-52	-47	-47	N/A
3/31/2023	N/A	-61	-53	-53	N/A
12/31/2022	N/A	-62	-57	-57	N/A
9/30/2022	N/A	-65	-57	-57	N/A
6/30/2022	N/A	-66	-53	-53	N/A
3/31/2022	N/A	-63	-42	-42	N/A
12/31/2021	N/A	-58	-43	-43	N/A
9/30/2021	N/A	-53	-39	-39	N/A
6/30/2021	N/A	-46	-37	-37	N/A
3/31/2021	N/A	-39	-36	-36	N/A
12/31/2020	N/A	-38	-37	-37	N/A
9/30/2020	N/A	-39	-40	-40	N/A
6/30/2020	N/A	-49	-42	-42	N/A
3/31/2020	N/A	-55	-48	-48	N/A
12/31/2019	N/A	-61	-45	-45	N/A
9/30/2019	N/A	-58	-42	-42	N/A
6/30/2019	N/A	-50	-41	-41	N/A
3/31/2019	N/A	-46	-35	-35	N/A
12/31/2018	N/A	-39	-30	-30	N/A
9/30/2018	N/A	-35	-27	-27	N/A
6/30/2018	N/A	-29	-24	-24	N/A
3/31/2018	N/A	-26	-23	-23	N/A
12/31/2017	N/A	-22	N/A	-19	N/A
9/30/2017	N/A	-20	N/A	-18	N/A
6/30/2017	N/A	-20	N/A	-17	N/A
3/31/2017	N/A	-19	N/A	-15	N/A
12/31/2016	N/A	-19	N/A	-15	N/A
9/30/2016	N/A	-18	N/A	-14	N/A
6/30/2016	N/A	-17	N/A	-14	N/A
3/31/2016	N/A	-15	N/A	-12	N/A
12/31/2015	N/A	-12	N/A	-9	N/A
9/30/2015	N/A	-10	N/A	-8	N/A
6/30/2015	N/A	-9	N/A	-6	N/A
3/31/2015	N/A	-12	N/A	-6	N/A
12/31/2014	N/A	-10	N/A	-5	N/A
9/30/2014	N/A	-6	N/A	-4	N/A
6/30/2014	N/A	-3	N/A	-3	N/A
3/31/2014	N/A	5	N/A	-2	N/A
12/31/2013	N/A	1	N/A	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ALDX wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: ALDX wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: ALDX wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: ALDXDie Einnahmen des Unternehmens (47.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: ALDXDie Einnahmen des Unternehmens (47.2% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ALDX wird voraussichtlich in 3 Jahren unrentabel sein.

Aldeyra Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates upgraded to US$0.18 loss

Forecast to breakeven in 2026

Consensus EPS estimates fall by 163%

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2024

Recent updates

Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease

Consensus EPS estimates upgraded to US$0.18 loss

Forecast to breakeven in 2026

Consensus EPS estimates fall by 163%

Aldeyra Therapeutics, Inc. Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease

No longer forecast to breakeven

New minor risk - Profitability

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

New minor risk - Profitability

No longer forecast to breakeven

Forecast to breakeven in 2024

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease

CEO, President & Director recently sold US$581k worth of stock

CEO, President & Director notifies of intention to sell stock

Forecast to breakeven in 2024

New minor risk - Profitability

Forecast to breakeven in 2024

Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?

Consensus revenue estimates increase by 55%

Consensus revenue estimates increase by 57%

Aldeyra Therapeutics, Inc. Announces Positive Top-Line Results from A Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis

Consensus revenue estimates increase by 600%

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Consensus revenue estimates decrease by 82%, EPS upgraded

Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?

New minor risk - Market cap size

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Announces Update of U.S. Food and Drug Administration Relating to the New Drug Application for Reproxalap for the Treatment of the Signs and Symptoms of Dry Eye Disease

Consensus revenue estimates decrease by 61%, EPS upgraded

Price target decreased by 13% to US$17.86

CEO, President & Director exercised options and sold US$492k worth of stock

Frank R. Cruz Announces Securities Fraud Lawsuit Against Aldeyra Therapeutics, Inc

Consensus revenue estimates increase by 36%

Consensus revenue estimates decrease by 73%, EPS upgraded

Holzer & Holzer, LLC Files Class Action Lawsuit Against Aldeyra Therapeutics, Inc

Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX--629 in Patients with Chronic Cough

Consensus revenue estimates increase by 15%

Aldeyra Therapeutics, Inc. Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE--2 Trial of Reproxalap in Allergic Conjunctivitis

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 30, 2023

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

Consensus revenue estimates decrease by 41%, EPS upgraded

Price target increased by 8.4% to US$21.83

Aldeyra Therapeutics, Inc. Advances Investigational Oral RASP Modulator ADX--629 Into New Phase 2 Systemic Disease Trials

Aldeyra Therapeutics, Inc. Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease

Forecast to breakeven in 2025

Insufficient new directors

Aldeyra Therapeutics, Inc. Submits New Drug Application to the U.S. Food and Drug Administration for Adx-2191 for the Treatment of Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics, Inc. Announces Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial

Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA

Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?

Aldeyra Therapeutics, Inc. Achieves Primary Endpoint in Part 1 of Phase 3 Guard Trial of Adx-2191 in Proliferative Vitreoretinopathy

Aldeyra Therapeutics, Inc. Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA

Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment

Insider recently bought US$1.1m worth of stock

Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?

Aldeyra Therapeutics, Inc. Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trial

Aldeyra says trial for dry eye disease candidate reached key goals

CEO, President & Director recently bought US$60k worth of stock

Aldeyra Therapeutics, Inc. Achieves Primary Endpoint in Phase 3 Tranquility-2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye Disease

Aldeyra Therapeutics, Inc. Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease

Aldeyra Therapeutics, Inc. Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease

Aldeyra Therapeutics Announces That Post-Hoc Analysis Using Computer Automated Grading of Phase 3 Tranquility Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap over Vehicle for Primary Endpoint of Ocular Redness

Price target decreased to US$20.89

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 07, 2022